Impact of asparaginase discontinuation on outcomes in ALL

The addition of asparaginase to ALL regimens provides significant patient benefits. However, it is often discontinued because of toxicities, such as hypersensitivity reactions. Numerous studies have demonstrated that discontinuation of asparaginase is associated with inferior outcomes in patients with ALL. Thus, in patients who experience hypersensitivity reactions or silent inactivation, switching to an asparaginase with a distinct immunogenic profile is recommended to enable them to complete the full course of asparaginase treatment. Results from the Children’s Oncology Group study AALL1931 demonstrate that the asparaginase Erwinia chrysanthemi (recombinant)-rywn is a reliable option for patients with ALL switching from E. coli-based asparaginase to Erwinia-derived asparaginase treatment, consequently enabling patients to achieve the full clinical benefit of remaining on therapy. 

This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.